NT5C1A Antibodies

Cytosolic 5'-nucleotidase 1A (NT5C1A)

Dephosphorylates the 5' and 2'(3')-phosphates of deoxyribonucleotides and has a broad substrate specificity. Helps regulate adenosine levels in heart during ischemia and hypoxia.

.

Gene Information

Human
Gene Name:	NT5C1A
Uniprot:	Q9BXI3
Entrez:	84618

Family

Belongs to:
5'-nucleotidase type 3 family

Alternative Names

5'-nucleotidase, cytosolic IA; AMP-specific 5'-NT; CN1; CN1A; CN-I; CN-IA; cytosolic 5' nucleotidase, type 1A; cytosolic 5'-nucleotidase 1A; Cytosolic 5'-nucleotidase IA; EC 3.1.3.5; MGC119199; MGC119201

Molecular Weight

Mass (kDA):
41.021 kDA

Genomic Context

Human
Location:	1p34.2
Sequence:	1; NC_000001.11 (39659121..39672038, complement)

Tissue Specificity

Highly expressed in skeletal muscle. Detected at intermediate levels in heart, brain, kidney and pancreas.

Subcellular Localizations

Cytoplasm.

Diseases

• Insulin Resistance
• Diabetes Mellitus, Non-insulin-dependent
• Obesity
• Diabetes Mellitus, Experimental
• Diabetes Mellitus

Interacting Proteins

• WDYHV1

Pathways

• Transport
• Lipid Oxidation
• Gene Silencing
• Glucose Transport

PTMs

• Phosphorylation

• Oxidation

• Dephosphorylation

Research Areas

• Lipid and Metabolism

For details, visit:
bosterbio.com/bosterbio-gene-info-cards/NT5C1A

Best Uses Of The NT5C1A Marker From Boster Bio

You have found the right place if you are looking for antibodies against the NT5C1A proteins. Boster Bio offers high-affinity primary antibodies that have been validated for use in Western Blotting, Immunohistochemistry, and ELISA. Boster antibodies were extensively validated in research labs over years, so you can trust them.

NT5C1A can be described as a cytosolic cytosolic five'-nucleotidase IA

To determine the role of NT5C1A within inflammatory myopathies, we studied the antibody response in a large number of patients with idiopathic inflammatory myopathies. This included patients with non-inflammatory myopathies, including dermatomyositis or inclusion body myositis. The anti-NT5C1A antibody levels were associated with disease severity and clinical signs as well as disease activity.

The study also found the presence of anti NT5C1A antibodies in sera taken from sIBM patient. This study also revealed that autoantibodies were present against the full-length recombinant human protein. It also showed autoantibodies against other autoimmune meopathy antigens (PL-12 and sIBM, as well as SAE).

A small percentage of people are positive for anti-NT5C1A antibody. They are not associated either with malignancy, interstitial pneumonia disease, or antisynthetase Syndrome. They are not diagnostic indicators of inflammatory conditions. The test has a low sensitivity and specificity as well as a high negative predictive score.

This study not only demonstrates the presence NT5C1A within PDAC patients but also identifies a unique NT5C1A mark. Researchers have shown that patients with anti NT5C1A antibodies are significantly younger than patients who do not have it. They also have lower serum CK levels and more dysphagia.

The study includes sera of patients with pSS and SLE. Patients were recruited to each center's biobank. pSS and SLE were diagnosed using 1997 American College of Rheumatology criteria, and the sera of patients with pSS were obtained from European centers. This study may have revealed a role in SLE for cN-1A. However, more research is needed to confirm NT5C1A's role in autoimmune disorders.

IBM has been known to have anti-NT5C1A proteins. They can also be detected in non-IBM individuals. These results suggest that anti-NT5C1A antibodies do not have a significant association with survival rates or prognosis. These results are important for early diagnosis of IBM. These findings are not of much utility but they do suggest that cN1A antibody should be considered for IBM patients.

It is a B cells response

Patients with SLE or other similar diseases have been shown to have antibodies against the NT5C1A mark. The diagnostic cutoff was 600 MFU, which is two standard deviations below the mean value of healthy controls. This gave a sensitivity/specificity of 48.8%/91.8% respectively. In the following paragraphs we will discuss the diagnostic potential of these antibodies as well as the significance and implications of their findings.

ALBIA can detect anti-NT5C1A antibodies. In addition, this assay has a high specificity and sensitivity, which may explain its use in the diagnosis of sIBM. Positive results for anti–NT5C1A antibodies should be interpreted with the context and clinical findings. IIM patients should also be screened. Further research is needed to determine the pathogenic mechanisms and correlate high titer anti–NT5C1A antibody levels to disease characteristics.

Anonymous venous blood samples were collected in this study. The cells were stained with mouse anti-human antibodies-fluorophore conjugates, and memory B cells were identified by flow cytometry. DCK was found in memory CD4+T cells and memory cells, while NT5C1B in neutrophils was not detected. This study shows DCK can activate B cell responses to the NT5C1A mark.

This study showed that patients with sIBM are more likely to have anti-NT5C1A antibodies. This suggests that antibodies may play a role in causing disease. In addition, these antibodies are associated with higher incidence of autoimmune diseases, which arise from the immune system's response to native molecules. So what is the relationship between B cell responses and sIBM

Mouse lines were created using a heterozygous background to test the immunological significance NT5C1A gene expression. To generate B-cell responses in these mice, cDNA encoding the NT5C1A gene was introduced into the pET24d expression vector. After transferring cDNA into the vector, the mice were genotyped. The reverse primer sequences of the cDNA were AAGGGTGATGTCTAGGG.

It is a more reliable and reliable method to detect anti NT5c1A human sera

There is a better way to detect anti NT5c1a levels in human sera. This method detects anti-NT5c1A more accurately and sensitively than peptide based ELISA. Anti-NT5c1a is considered positive for serum with OD450 values that are three standard deviations or more than the mean of the controls.

Although the ALBIA method has a low sensitivity and high specificity for anti-NT5c1A, it has moderate sensitivity. While anti-NT5c1A antibodies found in serum from patients with sIBM are associated with muscle weakness, they do not correlate with specific IIF staining patterns. Therefore, screening with HEp-2 substrate is unlikely to be a reliable predictor of the presence of autoantibodies in human sera.

The Euroline Autoimmune Inflammatory Myopathies 16 Ag (IgG) immunoblot allows for the detection of anti-cN-1A in human sera. This test uses a human sera diluted to 1:250 and a recombinant CN-1A protein of 0.4 mg/ml. Additionally, the antigen was analysed by denaturing electronesis using a NuPAGE Decex 4-12% Bis Tris gradient gel system.

Anti-NT5c1A antibody biomarkers are a biomarker in sporadic myositis. They have been detected as much as 27 percent in JDM patients. A more sensitive anti-NT5c1A antibody assay was created using sera from 117 JDM sufferers. Its sensitivity was improved, and the results of this study were published in Nature.

Although anti-NT5c1A antibodies are associated with increased disease severity in sIBM patients, they are not related to pathological or phenotypic differences between patients and healthy controls. In mice, anti-NT5c1A antibodies induced macrophage infiltration. This resulted in the formation of sarcoplasmic aggregates in the myofibers.

Another method to detect anti NT5c1a is to look for antibodies to the 43-kDa antigen. This method has a 90% specificity. However, the sensitivity ranges from thirty-five percent to seventy-six percent in IBM. The sensitivity rises to seventy six percent when all three isotypes are detected.

It is associated to a higher chance of having an sIBM

Among the autoimmune muscle diseases, sIBM is characterized by the presence of autoantigens in the serum. This autoantigen, NT5C1A, has been associated with an increased risk of developing the disorder. Other autoimmune disorders like Sjogren's syndrome have also been shown to be at higher risk than the autoantigen.

Two polymorphisms in the NOTCH4 gene have been linked to sIBM. Genetic studies have shown this association. These polymorphisms have been associated with an increased risk of developing the disease. They can also be used to identify individuals who are at highest risk for developing sIBM. These gene polymorphisms can influence the binding and affinity for the NOTCH4 receptor. They may also influence the presentation of gene products at the cell surface.

A higher risk of sIBM is associated with anti-NT5C1A antibodies in those with a positive serum test. Interestingly though, anti-NT5C1A antibodies do not correlate to any specific feature of the illness. However, those with higher serum levels did experience a more severe course. It is unknown if the antiNT5C1A-protein is the primary or secondary cause of sIBM. Further research is needed to determine if antiNT5C1A antibodies are associated a higher risk of sIBM.

It was found that patients with a CD8/MHC-1 complex had an increased risk of sIBM when they had anti-NT5C1A antibody antibodies. The ineffectiveness or absence of treatment was not associated with antibody positivity. Patients with sIBM were found to have positive anti-NT5C1A antibodies even though the antibodies were not in their serum.

Anti-NT5C1A antibodies can be detected using ALBIA. Patients with sIBM have a sensitivity of 48.8%, and a specificity of 91.8%. IIF on commercial HEp-2 HEp-2 substrate is ineffective for screening for anti NT5C1A. Furthermore, the test should be interpreted in context of clinical findings. Clinicians should exercise caution when using positive results in patients with IIM. Further research is needed on the pathogenic mechanisms of IIM and how to correlate high titer antiNT5C1A with disease characteristics.